Breakout Ventures Associates has led a $40 million Series A funding round for Noetik, a biotech firm with aspirations to develop AI-driven solutions for cancer treatment. This move, somewhat surprising given Amy Schulman’s background at Pfizer and Alnylam, highlights an evolving strategy in biotech investments. Schulman, formerly Pfizer’s chief legal officer and now chairing Alnylam’s board, adds a noteworthy layer of credibility to Noetik’s innovative approach. With this substantial financial backing, Noetik aims to leverage artificial intelligence to make significant advancements in the fight against cancer.
Biotechnology, Artificial Intelligence, Healthcare, Private Equity,USA
https://endpts.com/noetik-raises-40m-series-a-to-advance-ai-ambitions-in-cancer-with-an-unlikely-lead-investor/